Italia markets closed

Chr. Hansen Holding A/S (0MR6.IL)

IOB - IOB Prezzo differito. Valuta in DKK.
Aggiungi a watchlist
551,50-1,10 (-0,20%)
Alla chiusura: 06:13PM GMT
Schermo intero
Chiusura precedente552,60
Aperto549,00
Denaro536,20 x 0
Lettera562,60 x 0
Min-Max giorno547,20 - 553,40
Intervallo di 52 settimane418,10 - 604,40
Volume86.019
Media Volume540.348
Capitalizzazione72,62B
Beta (5 anni mensile)0,30
Rapporto PE (ttm)42,55
EPS (ttm)12,96
Prossima data utiliN/D
Rendimento e dividendo (futuro)7,72 (1,79%)
Data ex dividendo13 ott 2023
Stima target 1AN/D
  • GlobeNewswire

    Chr. Hansen Holding A/S Interim Report Q4 2022/23

    October 12, 2023 – Company announcement no. 9 Strong performance for the quarter despite a challenging environment Statement by CEO Mauricio Graber: “Supported by a strong Q4 performance, Chr. Hansen delivered a solid result for the first twelve months of the extended financial year 2022/23 at the upper end of our guidance with 11% organic revenue growth and an EBIT margin b.s.i. of 26.9%. Throughout the year, we have demonstrated the attractiveness of the markets we serve and the resilience of

  • GlobeNewswire

    Major shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP

    September 27, 2023 – Company announcement no. 8 Please see attachment. Contact information Investor RelationsAnders Mohr Christensen+45 2515 2364dkamc@chr-hansen.com Press RelationsSanne Seyer-Hansen+45 6038 6207dksash@chr-hansen.com About Chr. Hansen Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen, we are strongly positioned to drive positive change through

  • GlobeNewswire

    Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL. SEPTEMBER 4, 2023 On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies. Re